South West Regional Experience of Alpelisib and Fulvestrant in Patients with a PIK3CA Mutation

Purpose: PIK3CA mutations occur in approximately 40% of patients with hormone receptor-positive and human epidermal growth factor 2-negative breast cancers. The SOLAR-1 trial, a randomised phase III placebo controlled trial compared alpelisib, a PIK3CA inhibitor, with fulvestrant to placebo with fulvestrant [1]. At a median follow-up of 20 months, the progression-free survival in patients with a PIK3CA mutation receiving alpelisib and fulvestrant was 11 months compared with 5.7 months in the placebo plus fulvestrant group.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research